Is BioNTech Stock a Buy Now?

BioNTech (NASDAQ: BNTX) is the lesser-known member of the pair -- which also includes Pfizer -- that developed and marketed Comirnaty, one of the leading coronavirus vaccines on the market. However, it was originally BioNTech that created this clinical compound, which speaks highly to the biotech's innovative potential.

Still, like many other vaccine makers that made a fortune during the pandemic, with the passing of the state of emergency, BioNTech's stock has substantially underperformed the market this year. Should investors buy the dip on this biotech stock?

Source Fool.com

Pfizer Inc. Aktie

Pfizer Inc. muss heute leichte Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -0,81 % tiefer.
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.19 € bedeuten.

Like: 0

BNTX

Teilen